These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 24814143)

  • 1. The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme.
    Bambury RM; Morris PG
    Expert Rev Anticancer Ther; 2014 Aug; 14(8):955-64. PubMed ID: 24814143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitors in tackling recurrent glioblastoma.
    Hundsberger T; Reardon DA; Wen PY
    Expert Rev Anticancer Ther; 2017 Jun; 17(6):507-515. PubMed ID: 28438066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
    Simpson L; Galanis E
    Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in therapy for glioblastoma.
    Clarke J; Butowski N; Chang S
    Arch Neurol; 2010 Mar; 67(3):279-83. PubMed ID: 20212224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving strategies: future treatment of glioblastoma.
    Chamberlain M
    Expert Rev Neurother; 2011 Apr; 11(4):519-32. PubMed ID: 21469925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review.
    Mohtashami E; Shafaei-Bajestani N; Mollazadeh H; Mousavi SH; Jalili-Nik M; Sahebkar A; Afshari AR
    Curr Drug Metab; 2020; 21(8):564-578. PubMed ID: 32664839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topics in chemotherapy, molecular-targeted therapy, and immunotherapy for newly-diagnosed glioblastoma multiforme.
    Okonogi N; Shirai K; Oike T; Murata K; Noda SE; Suzuki Y; Nakano T
    Anticancer Res; 2015 Mar; 35(3):1229-35. PubMed ID: 25750269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of glioblastoma: State of the art and future directions.
    Tan AC; Ashley DM; López GY; Malinzak M; Friedman HS; Khasraw M
    CA Cancer J Clin; 2020 Jul; 70(4):299-312. PubMed ID: 32478924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options for recurrent glioblastoma: pitfalls and future trends.
    Franceschi E; Tosoni A; Bartolini S; Mazzocchi V; Fioravanti A; Brandes AA
    Expert Rev Anticancer Ther; 2009 May; 9(5):613-9. PubMed ID: 19445578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent glioblastoma: a fresh look at current therapies and emerging novel approaches.
    Gilbert MR
    Semin Oncol; 2011 Dec; 38 Suppl 4():S21-33. PubMed ID: 22078645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New molecularly targeted therapies for glioblastoma multiforme.
    Polivka J; Polivka J; Rohan V; Topolcan O; Ferda J
    Anticancer Res; 2012 Jul; 32(7):2935-46. PubMed ID: 22753758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
    Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
    Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapies in glioblastoma multiforme.
    McNamara MG; Mason WP
    Expert Rev Anticancer Ther; 2012 May; 12(5):643-54. PubMed ID: 22594899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New therapeutic options in therapy of glioblastoma multiforme].
    Lakomý R; Burkon P; Burkonová D; Jancálek R
    Klin Onkol; 2010; 23(6):381-7. PubMed ID: 21351415
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The newest perspectives on the treatment of glioblastoma multiforme].
    Cholewa H; Duda K; Łabuzek K; Okopień B
    Pol Merkur Lekarski; 2014 Aug; 37(218):119-23. PubMed ID: 25252449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.
    Chinot OL
    Expert Rev Anticancer Ther; 2012 Nov; 12(11):1413-27. PubMed ID: 23249106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced MRI assessment to predict benefit of anti-programmed cell death 1 protein immunotherapy response in patients with recurrent glioblastoma.
    Qin L; Li X; Stroiney A; Qu J; Helgager J; Reardon DA; Young GS
    Neuroradiology; 2017 Feb; 59(2):135-145. PubMed ID: 28070598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontiers in targeting glioma stem cells.
    Frosina G
    Eur J Cancer; 2011 Mar; 47(4):496-507. PubMed ID: 21185169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.